Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.
David M. Brown,Quan Dong Nguyen,Dennis M. Marcus,David S. Boyer,Sunil S. Patel,Leonard Feiner,Patricio G. Schlottmann,Amy Chen Rundle,Jiameng Zhang,Roman G. Rubio,Anthony P. Adamis,Jason S. Ehrlich,J Jill Hopkins +12 more
Reads0
Chats0
TLDR
The strong VA gains and improvement in retinal anatomy achieved with ranibizumab at month 24 were sustained through month 36, and the incidence of serious adverse events potentially related to systemic vascular endothelial growth factor inhibition remained low over time.About:
This article is published in Ophthalmology.The article was published on 2013-10-01 and is currently open access. It has received 724 citations till now. The article focuses on the topics: Ranibizumab & Macular edema.read more
Citations
More filters
Journal ArticleDOI
VEGF in Signaling and Disease: Beyond Discovery and Development.
TL;DR: This review will highlight critical nodal points in VEGF biology, including recent developments in immunotherapy for cancer and multitarget approaches in neovascular eye disease.
Journal ArticleDOI
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema.
John A. Wells,Adam R. Glassman,Allison R. Ayala,Lee M. Jampol,Lloyd Paul Aiello,Andrew N. Antoszyk,Bambi Arnold-Bush,Carl W. Baker,Neil M. Bressler,David J. Browning,Michael J. Elman,Frederick L. Ferris,Scott M. Friedman,Michele Melia,Dante J. Pieramici,Jennifer K. Sun,Roy W. Beck +16 more
TL;DR: Intravitreous aflibercept, bevacizumAB, or ranibizumab improved vision in eyes with center-involved diabetic macular edema, but the relative effect depended on baseline visual acuity.
Journal ArticleDOI
Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema.
David S. Boyer,Young Hee Yoon,Rubens Belfort,Francesco Bandello,Raj K. Maturi,Albert J. Augustin,Xiao-yan Li,Harry Cui,Yehia Hashad,Scott M. Whitcup +9 more
TL;DR: The DEX implant 0.7 mg and 0.35 mg met the primary efficacy endpoint for improvement in BCVA, and the safety profile was acceptable and consistent with previous reports.
Journal ArticleDOI
Intravitreal aflibercept for diabetic macular edema.
Jean-François Korobelnik,Diana V. Do,Ursula Schmidt-Erfurth,David S. Boyer,Frank G. Holz,Jeffrey S. Heier,Edoardo Midena,Peter K. Kaiser,Hiroko Terasaki,Dennis M. Marcus,Quan Dong Nguyen,Glenn J. Jaffe,Jason S. Slakter,Christian Simader,Yuhwen Soo,Thomas Schmelter,George D. Yancopoulos,Neil Stahl,Robert Vitti,Alyson J. Berliner,Oliver Zeitz,Carola Metzig,David M. Brown +22 more
TL;DR: Overall incidences of ocular and nonocular adverse events and serious adverse events, including the Anti-Platelet Trialists' Collaboration-defined arterial thromboembolic events and vascular deaths, were similar across treatment groups, and IAI was well-tolerated.
Journal ArticleDOI
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.
John A. Wells,Adam R. Glassman,Allison R. Ayala,Lee M. Jampol,Neil M. Bressler,Susan B. Bressler,Alexander J. Brucker,Frederick L. Ferris,G. Robert Hampton,Chirag Jhaveri,Michele Melia,Roy W. Beck +11 more
TL;DR: All 3 anti-VEGF groups showed VA improvement from baseline to 2 years with a decreased number of injections in year 2, and among eyes with worse baseline VA, a flibercept had superior 2-year VA outcomes compared with bevacizumab, but superiority of aflibercept over ranibizumAB, noted at 1 year, was no longer identified.
References
More filters
Journal ArticleDOI
Ranibizumab for Neovascular Age-Related Macular Degeneration
Philip J. Rosenfeld,David M. Brown,Jeffrey S. Heier,David S. Boyer,Peter K. Kaiser,Carol Chung,Robert Y. Kim +6 more
TL;DR: Intravitreal administration of ranibizumab for 2 years prevented vision loss and improved mean visual acuity, with low rates of serious adverse events, in patients with minimally classic or occult (with no classic lesions) choroidal neovascularization secondary to age-related macular degeneration.
Journal ArticleDOI
Standards of Medical Care in Diabetes—2012
TL;DR: These standards of care are intended to provide clinicians, patients, researchers, payers, and other interested individuals with the components of diabetes care, general treatment goals, and tools to evaluate the quality of care.
Journal Article
Collaborative overview of randomized trials of antiplatelet therapy .1. prevention of death, myocardial-infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
R Altman,L Carreras,R Diaz,E Figueroa,E Paolasso,J C Parodi,J F Cade,G Donnan,M J Eadie,T P Gavaghan,E F Osullivan,D Parkin,Renny Jtg.,C Silagy,H Vinazzer,F Zekert,H Adriaensen,J M Bertrandhardy,M Bran,J L David,J Dricot,E Lavennepardonge,R Limet,A Lowenthal,M Moriau,S Schapira,P Smets,J Symoens,R Verhaeghe,Marc Verstraete,A Atallah,H Barnett,R Batista,J Blakely,J A Cairns,R Cote,J Crouch,G Evans,J M Findlay,M Gent,Y Langlois,J Leclerc,J Norris,G F Pineo,P J Powers,R Roberts,L Schwartz,J Sicurella,W Taylor,P Theroux,Alexander G.G. Turpie,R D Weisel,J Cui,L Liu,J Pirk,C Bay,G Boysen,J B Knudsen,P Petersen,P S Sorensen,H K Tonnesen,P T Harjola,J C Arcan,B Balkau,J Blanchard,J P Boissel,B Boneu,M G Bousser,M Brochier,M Cloarec,G Cribier,M Dechavanne,P Drouin,E Eschwege,B Guiraudchaumeil,R Hugonot,A Leizorovicz,Y Loria,L Michat,J Mirouze,E Panak,J Pasteyer,A Rascol,L Revol,Maarten Van Roy,J Selles,G Slama,C Starkman,M Teule,N Thibult,M Verry,F W Albert,K Andrassy,K Breddin,R Eckel,A Encke,J Frohlich,B Hartung,H W Heiss,H Hess,B Hofling,D Krause,G Latta,H Linke,D Loew,R Lorenz,K Middleton,G Novak,M Oldendorf,N Pfluger,D Raithel,R Reuter,G Schettler,J Schnitker,W Schoop,H Stiegler,K Uberla,G Vogel,M Weber,I Welbers,E Zeitler,G Arapakis,T Chan,C K Mok,R Szabo,N P Misra,K Reddy,G A Fitzgerald,A Apollonio,F Balsano,A Basellini,L Candelise,Mariella Catalano,N Ciavarella,G Ciuffetti,S Coccheri,M Cortellaro,G Corvi,V Coto,Giovanni Davì,R Decaterina,T Diperri,C Fieschi,R Gentile,L Gregoratti,Paolo Gresele,M Lavezzari,A Libretti,B Magnani,G.G. Nenci,G Pagano,Carlo Patrono,L Pedrini,M Pini,Paolo Prandoni,F Romeo,F Rovelli,G Rudelli,G Ruvolo,G P Signorini,G Tognoni,Francesco Violi,T Fujimori,M Kageyama,T Katsumura,S Kitamura,K Maeda,A Suzuki,H Tohgi,S Uchiyama,H Utsumi,A M Garcia,A Algra,Denottolander Gjh.,Kupper Ajf.,J Vangijn,H Hart,L J Kappelle,P J Koudstaal,T Lemmens,J Lodder,M Pannebakker,P W Serruys,A Vandenbelt,J Vandermeer,A B Vandervijgh,Verheugt Fwa.,G Veth,J Dale,K A Johannessen,E Thaulow,P Popescu,N Tiberiu,Aznar Jrd.,E Esmatjes,P Guiteras,J Lasierra,P Lopeztrigo,A Oriol,L Pomar,E Rocha,F D Sanchez,J Sanchorieger,G Sanz,Berglund Ulf.,C Blomstrand,M Boberg,M Britton,C E Elwin,C Helmers,J Holm,L Janzon,S Juulmoller,H Mulec,J E Olsson,S Persson,G Rasmanis,A Rosen,K Samuelsson,J Soreff,N Wahlgren,L Wallentin,H R Baur,M Bokslag,A Bollinger,B Meier,M Pfisterer,C Sitthiamorn,E J Acheson,P Appleby,A W Asscher,A Aukland,Colin Baigent,S Bala,A H Barnett,P Bell,S Bews,Born Gvr.,J P Branagan,N Brooks,M J Brown,N L Browse,R Capildeo,M Carmalt,A E Carter,I Chalmers,Mike Clarke,Robert Clarke,Clyne Cac.,Rory Collins,Cooke,G Coutts,D H Cove,P S Crowther,W F Cuthbertson,D Debono,C Dickerson,J P Dickinson,Richard Doll,J A Dormandy,D Dunbabin,S Ell,P Elphinstone,P Elwood,V Englishby,B Farrell,C Fiskerstrand,M Flather,T Foley,T Foulds,K M Fox,Peter Franks,H Fraser,T Gardecki,M Gawel,A E Gent,A H Gershlick,J Godwin,M Goldman,C Gray,D Gray,Richard Gray,H Handoll,G Hankey,Harrison Mjg.,N Henderson,S Heptinstall,S F Hobbiger,E W Jones,Jones Nag.,S Jost,D Julian,J Kellett,R C Kester,G Lowe,J Mackenzie,C N McCollum,G Mead,T W Meade,D Mendelow,J C Miller,G K Morris,C Nichol,M Noble,Obrien,M Ogier,Sarah Parish,M J Parry,Richard Peto,Janet T. Powell,P Pozzilli,N Qizilbash,A Rahman,S M Rajah,D H Richards,S Richards,Ruth M. Ripley,V C Roberts,F C Rose,Russell Rwr.,P C Rubin,C V Ruckley,Peter Sandercock,Shaw Mdm.,K M Shaw,J H Shelley,J Slattery,Peter Sleight,S J Smith,P Stewartlong,P M Sweetnam,Tansey Mjb.,H Tindall,J Turney,H M Tyler,N C Varey,M P Vessey,M G Walker,M A Walker,C P Warlow,R G Wilcox,H Willems,E H Wood,E Wynjones,H P Adams,B Barton,R F Bedford,B L Bick,S Bingham,B G Brown,T Bryant,J Buring,C F Cabot,P Canner,J Chesebro,O D Chrisman,G P Clagett,J A Colwell,M Dyken,D Ellis,W S Fields,C Furberg,V Fuster,S Goldman,J Granett,R M Green,D Green,R Hardy,L A Harker,W H Harris,R G Hart,W K Hass,Charles H. Hennekens,D Hill,M Hume,M C Igloe,G Johnson,S Jonas,G Knatterud,T R Kohler,N J Lembo,D Lewis,E Lockhart,P Majerus,Mcenany,R Mckenna,J L Mehta,J S Meyer,B Molony,T Moritz,D M Nicoloff,G Nycz,H Ono,G A Pantely,S J Phillips,Paul M. Ridker,J T Robertson,R Rothbart,E W Salzman,R D Sautter,R C Schlant,J A Schoenberger,M V Sengekontacket,G Sharma,P Steele,K P Steinnagel,J Stratton,J M Sullivan,G Timmis,J F Toole,Walker,S Weisman,C W White,M Wirecki,D Wombolt,R Wong,Salim Yusuf,K Zadina,D Zucker +418 more
TL;DR: There was no appreciable evidence that either a higher aspirin dose or any other antiplatelet regimen was more effective than medium dose aspirin in preventing vascular events, so in each of the four main high risk categories overall mortality was significantly reduced.
Journal ArticleDOI
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
David M. Brown,Peter K. Kaiser,Mark Michels,Gisèle Soubrane,Jeffrey S. Heier,Robert Y. Kim,Judy P. Sy,Susan Schneider +7 more
TL;DR: Ranibizumab was superior to verteporfin as intravitreal treatment of predominantly classic neovascular age-related macular degeneration, with low rates of serious ocular adverse events and treatment improved visual acuity on average at 1 year.
Related Papers (5)
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema.
Intravitreal aflibercept for diabetic macular edema.
Jean-François Korobelnik,Diana V. Do,Ursula Schmidt-Erfurth,David S. Boyer,Frank G. Holz,Jeffrey S. Heier,Edoardo Midena,Peter K. Kaiser,Hiroko Terasaki,Dennis M. Marcus,Quan Dong Nguyen,Glenn J. Jaffe,Jason S. Slakter,Christian Simader,Yuhwen Soo,Thomas Schmelter,George D. Yancopoulos,Neil Stahl,Robert Vitti,Alyson J. Berliner,Oliver Zeitz,Carola Metzig,David M. Brown +22 more